DOCSLIB.ORG

Chronic Thrombocytopenia As the Initial Manifestation of STIM1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chronic Thrombocytopenia As the Initial Manifestation of STIM1 Chronic Thrombocytopenia as the Initial Manifestation of STIM1-Related Disorders Anjali Sura, MD,a Joseph Jacher, MS,b Erin Neil, DO,c Kathryn McFadden, MD,d Kelly Walkovich, MD,e Mark Hannibal, MD, PhDb Pediatric thrombocytopenia has a wide differential diagnosis, and recently, abstract genetic testing to identify its etiology has become more common. We present a case of a 16-year-old boy with a history of chronic moderate thrombocytopenia, who later developed constitutional symptoms and bilateral hand edema with cold exposure. Laboratory evaluation revealed evidence both of inflammation and elevated muscle enzymes. These abnormalities persisted over months. His thrombocytopenia was determined to be immune mediated. Imaging revealed lymphadenopathy and asplenia, Divisions of aPediatric Rheumatology, bPediatric Genetics, and a muscle biopsy was consistent with tubular aggregate myopathy. cPediatric Neurology, and ePediatric Hematology-Oncology d Ophthalmology evaluation noted photosensitivity, pupillary miosis, and iris and Department of Pathology, University of Michigan, Ann Arbor, Michigan hypoplasia. Genetic testing demonstrated a pathogenic variant in STIM1 consistent with autosomal dominant Stormorken syndrome. Our case is novel Mr Jacher, Ms Sura, Ms Neil, Mr Hannibal, Ms McFadden, and Ms Walkovich all participated in because of the overlap of phenotypes ascribed to both gain-of-function and literature review, drafted the initial manuscript, and loss-of-function pathogenic variants in STIM1, thereby blurring the then reviewed and revised the manuscript; and all distinctions between these previously described syndromes. Pediatricians authors approved the final manuscript as submitted and agree to be accountable for all aspects of should consider checking muscle enzymes when patients present with the work. thrombocytopenia and arthralgia, myalgia, and/or muscle weakness. Our case DOI: https://doi.org/10.1542/peds.2019-2081 highlights the importance of both multidisciplinary care and genetic testing in Accepted for publication Oct 28, 2019 cases of chronic unexplained thrombocytopenia. By understanding the ’ Address correspondence to Anjali Sura, MD, underlying genetic mechanism to a patient s thrombocytopenia, providers are Pediatric Rheumatology, SUNY Upstate, 725 Irving better equipped to make more precise medical management Ave, Suite 805, Syracuse, NY 13210. E-mail: suraa@ recommendations. upstate.edu PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275). Copyright © 2020 by the American Academy of Thrombocytopenia, defined as a platelet childhood are due to genetic pathogenic Pediatrics count ,150 000 K/mL, is a commonly variants that disrupt normal platelet FINANCIAL DISCLOSURE: The authors have indicated found laboratory abnormality in development and/or platelet function.1 they have no financial relationships relevant to this childhood. Many cases of Traditionally, inherited article to disclose. thrombocytopenia are spurious from thrombocytopenias have been FUNDING: No external funding. improper handling or inadequate classified on the basis of platelet size or POTENTIAL CONFLICT OF INTEREST: Mr Jacher is anticoagulation in the collection tube, by bleeding risk. However, because the a current employee of Blueprint Genetics, and his fi contributing to platelet clumping. Other bleeding risk associated with many of af liation during the drafting and submission of this cases are attributable to commonly article was as a full-time employee of the University the hereditary thrombocytopenias is of Michigan; the remaining authors have indicated acquired etiologies, such as infections, often of modest clinical impact, recent they have no potential conflicts of interest to medication exposures, malignancy, emphasis has been placed on managing disclose. underlying disorders that promote the other associated congenital immune-clearance, consumption, or abnormalities, such as limb anomalies To cite: Sura A, Jacher J, Neil E, et al. Chronic inadequate production of platelets. or hearing loss as well as their Thrombocytopenia as the Initial Manifestation of A smaller fraction of persistent or propensity for renal failure, bone STIM1-Related Disorders. Pediatrics. 2020;145(4): e20192081 intermittent thrombocytopenia cases in marrow aplasia, immunodeficiency, and Downloaded from www.aappublications.org/news by guest on September 26, 2021 PEDIATRICS Volume 145, number 4, April 2020:e20192081 CASE REPORT hematologic malignancy.2 Although persisted, prompting an evaluation (Invitae clinical diagnostic there has been recent hesitation in for inflammatory myositis and laboratory) identified a pathogenic using genetic testing for chronic a concurrent evaluation for the variant in STIM1 (c.910C.T, childhood thrombocytopenia,3 careful underlying etiology of his p.Arg304Trp [R304W]), consistent clinical phenotyping in concert with thrombocytopenia. MRI results of his with a diagnosis of autosomal genetic characterization of persistent lower extremities were negative for dominant STIM1-related conditions, thrombocytopenia is valuable to inflammatory myositis but including Stormorken syndrome. Of accurately gauge individual patient’s demonstrated bilateral hip and knee note, after the recognition of his risks and ensure a comprehensive effusions, notable inguinal STIM1-related variant, he was management plan (Table 1). lymphadenopathy (with many nodes evaluated by ophthalmology and measuring .1 cm), and hyperintense noted to have photosensitivity, miotic In this article, we describe a case of linear signal changes in the mid- and pupils that dilated poorly, and iris persistent moderate distal femurs with patchy red marrow hypoplasia. thrombocytopenia from infancy in signal. To further evaluate the a patient who presented with elevated creatine kinase, a muscle DISCUSSION elevated muscle enzymes and biopsy was performed, which fl in ammatory markers. Through revealed large vacuoles consistent This patient, with chronic isolated collaborative multispecialty with TAM on both light and electron thrombocytopenia of unknown evaluation, he was determined to microscopies (Fig 1). etiology, received an extensive have previously unrecognized tubular workup by a multidisciplinary team, Bone marrow aspiration biopsy result aggregate myopathy (TAM), including rheumatology, hematology, was negative for malignancy but lymphadenopathy, asplenia, and neurology, and genetics, to reveal fi significant for toxic granulation of subtle immunode ciency with a STIM1 pathogenic variant neutrophils, consistent with a unifying pathogenic variant in c.910C.T, p.Arg304Trp (R304W). If Stromal Interaction Molecule 1 inflammation. Circulating antibodies a hematologist was working alone to STIM1 against platelets (both ( ). This case highlights both the manage his thrombocytopenia, it is immunoglobulin G and value of multispecialty care and not likely that this etiology would immunoglobulin A) were detected, genetic testing in patients with have been discovered. In this case, the consistent with immune-mediated chronic thrombocytopenia while importance of both multidisciplinary STIM1 thrombocytopenia, although expanding the phenotype of care and genetic testing in cases of abdominal ultrasound could not gene-related variants. chronic unexplained identify a definite spleen. a-b double- thrombocytopenia is highlighted. By negative T cells were not elevated. understanding the underlying genetic PATIENT PRESENTATION The patient reported no recurrent or mechanism to a patient’s significant infections with unusual A 16-year-old Lebanese boy with thrombocytopenia, providers are organisms nor other a history of moderate better equipped to make more autoinflammatory features. thrombocytopenia (platelets ranging precise medical management Quantitative immunoglobulin levels from 60 000–100 000 K/mL), first recommendations. By using our for immunoglobulin G, documented at age 2 months, patient as an example, once the STIM1 immunoglobulin A, and presented with a sore throat, fatigue, pathogenic variant was identified, an immunoglobulin E were normal, back pain without muscle weakness, ophthalmology evaluation, abdominal whereas immunoglobulin M was and acute edema of his dorsal hands ultrasound, and neuropsychological mildly low (35 mg/dL; normal: after exposure to cold temperatures. testing were ordered. These 50–370 mg/dL). Flow cytometry His laboratory results were notable evaluations led to diagnoses of demonstrated normal T, B, and for leukocytosis (white blood count: photosensitivity, miotic pupils, iris natural killer (NK) cell absolute 11.4–20.0 K/µL with unremarkable hypoplasia, and asplenia. He will also counts. Lymphocyte mitogen differential) and elevations in his be continually monitored for proliferation testing was normal. inflammatory markers (erythrocyte contractures, ophthalmoparesis, and Lymphocyte antigen proliferation to sedimentation rate: 21–42 mm and cognitive delays and was counseled tetanus was negative, despite C-reactive protein: 0.5–2.7 mg/dL) regarding the infection risk related to adequate previous vaccination and and creatine kinase (528–973 IU/L). asplenia. Results of post-revaccination, although he did His hand edema improved with neuropsychological testing will guide demonstrate a response to Candida. naproxen. However, his laboratory whether further intervention is abnormalities, initially presumed to Genetic analysis via a 207-gene needed at school. Furthermore, be related to a viral process, Primary Immunodeficiency Panel individuals who know that they
Load more

Recommended publications
  • Snapshot: Formins Christian Baarlink, Dominique Brandt, and Robert Grosse University of Marburg, Marburg 35032, Germany
    SnapShot: Formins Christian Baarlink, Dominique Brandt, and Robert Grosse University of Marburg, Marburg 35032, Germany Formin Regulators Localization Cellular Function Disease Association DIAPH1/DIA1 RhoA, RhoC Cell cortex, Polarized cell migration, microtubule stabilization, Autosomal-dominant nonsyndromic deafness (DFNA1), myeloproliferative (mDia1) phagocytic cup, phagocytosis, axon elongation defects, defects in T lymphocyte traffi cking and proliferation, tumor cell mitotic spindle invasion, defects in natural killer lymphocyte function DIAPH2 Cdc42 Kinetochore Stable microtubule attachment to kinetochore for Premature ovarian failure (mDia3) chromosome alignment DIAPH3 Rif, Cdc42, Filopodia, Filopodia formation, removing the nucleus from Increased chromosomal deletion of gene locus in metastatic tumors (mDia2) Rac, RhoB, endosomes erythroblast, endosome motility, microtubule DIP* stabilization FMNL1 (FRLα) Cdc42 Cell cortex, Phagocytosis, T cell polarity Overexpression is linked to leukemia and non-Hodgkin lymphoma microtubule- organizing center FMNL2/FRL3/ RhoC ND Cell motility Upregulated in metastatic colorectal cancer, chromosomal deletion is FHOD2 associated with mental retardation FMNL3/FRL2 Constituently Stress fi bers ND ND active DAAM1 Dishevelled Cell cortex Planar cell polarity ND DAAM2 ND ND ND Overexpressed in schizophrenia patients Human (Mouse) FHOD1 ROCK Stress fi bers Cell motility FHOD3 ND Nestin, sarcomere Organizing sarcomeres in striated muscle cells Single-nucleotide polymorphisms associated with type 1 diabetes
    [Show full text]
  • MYH9-Related Platelet Disorders
    Reprinted with permission from Thieme Medical Publishers (Semin Thromb Hemost 2009;35:189-203) Homepage at www.thieme.com MYH9-Related Platelet Disorders Karina Althaus, M.D.,1 and Andreas Greinacher, M.D.1 ABSTRACT Myosin heavy chain 9 (MYH9)-related platelet disorders belong to the group of inherited thrombocytopenias. The MYH9 gene encodes the nonmuscle myosin heavy chain IIA (NMMHC-IIA), a cytoskeletal contractile protein. Several mutations in the MYH9 gene lead to premature release of platelets from the bone marrow, macro- thrombocytopenia, and cytoplasmic inclusion bodies within leukocytes. Four overlapping syndromes, known as May-Hegglin anomaly, Epstein syndrome, Fechtner syndrome, and Sebastian platelet syndrome, describe different clinical manifestations of MYH9 gene mutations. Macrothrombocytopenia is present in all affected individuals, whereas only some develop additional clinical manifestations such as renal failure, hearing loss, and presenile cataracts. The bleeding tendency is usually moderate, with menorrhagia and easy bruising being most frequent. The biggest risk for the individual is inappropriate treatment due to misdiagnosis of chronic autoimmune thrombocytopenia. To date, 31 mutations of the MYH9 gene leading to macrothrombocytopenia have been identified, of which the upstream mutations up to amino acid 1400 are more likely associated with syndromic manifestations than the downstream mutations. This review provides a short history of MYH9-related disorders, summarizes the clinical and laboratory character- istics, describes a diagnostic algorithm, presents recent results of animal models, and discusses aspects of therapeutic management. KEYWORDS: MYH9 gene, nonmuscle myosin IIA, May-Hegglin anomaly, Epstein syndrome, Fechtner syndrome, Sebastian platelet syndrome, macrothrombocytopenia The correct diagnosis of hereditary chronic as isolated platelet count reductions or as part of thrombocytopenias is important for planning appropri- more complex clinical syndromes.
    [Show full text]
  • Diagnosis of Inherited Platelet Disorders on a Blood Smear
    Journal of Clinical Medicine Article Diagnosis of Inherited Platelet Disorders on a Blood Smear Carlo Zaninetti 1,2,3 and Andreas Greinacher 1,* 1 Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, 17489 Greifswald, Germany; [email protected] 2 University of Pavia, and IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy 3 PhD Program of Experimental Medicine, University of Pavia, 27100 Pavia, Italy * Correspondence: [email protected]; Tel.: +49-3834-865482; Fax: +49-3834-865489 Received: 19 January 2020; Accepted: 12 February 2020; Published: 17 February 2020 Abstract: Inherited platelet disorders (IPDs) are rare diseases featured by low platelet count and defective platelet function. Patients have variable bleeding diathesis and sometimes additional features that can be congenital or acquired. Identification of an IPD is desirable to avoid misdiagnosis of immune thrombocytopenia and the use of improper treatments. Diagnostic tools include platelet function studies and genetic testing. The latter can be challenging as the correlation of its outcomes with phenotype is not easy. The immune-morphological evaluation of blood smears (by light- and immunofluorescence microscopy) represents a reliable method to phenotype subjects with suspected IPD. It is relatively cheap, not excessively time-consuming and applicable to shipped samples. In some forms, it can provide a diagnosis by itself, as for MYH9-RD, or in addition to other first-line tests as aggregometry or flow cytometry. In regard to genetic testing, it can guide specific sequencing. Since only minimal amounts of blood are needed for the preparation of blood smears, it can be used to characterize thrombocytopenia in pediatric patients and even newborns further.
    [Show full text]
  • Gri Trombosit Sendromu
    Cukurova Medical Journal Cukurova Med J 2017;42(2):360-362 ÇUKUROVA ÜNİVERSİTESİ TIP FAKÜLTESİ DERGİSİ DOI: 10.17826/cutf.322967 OLGU SUNUMU / CASE REPORT Gray platelet syndrome Gri trombosit sendromu Fatima Ayaz1, Saeed Bin Ayaz2, Sunila Tashfeen2, Muhammad Furrukh1 1Benazir Bhutto Hospital, Rawalpindi, Punjab, Pakistan 2Combined Military Hospital, Okara, Punjab, Pakistan Cukurova Medical Journal 2017;42(2):360-362 Abstract Öz Gray platelet syndrome (GPS) is an autosomal recessive Gri trombosit (platelet) sendromu (GPS), trombositopeni disorder characterized by thrombocytopenia and defective ve ışık mikroskopunda soluk görünen kusurlu platelets that appear pale on light microscope. Patients trombositlerle karakterize, otozomal resesif geçişli bir present with easy bruisability, nose bleeds, menorrhagia hastalıktır. Hastalarda kolay morarma, burun kanaması, and prolonged bleeding. There is no specific treatment for menoraji ve uzun kanamalar görülmektedir. GPS için GPS and the management includes anticipating risks and spesifik bir tedavi bulunmamaktadır dolayısı ile hastalığa preventing bleeding by avoiding drugs that impair platelet karşı, riskleri öngörmek ve kanamanın önlenmesi function. We present here report of a case who presented için trombosit fonksiyonunu bozan ilaçlardan kaçınmak with repeated episodes of abnormal bleeding and was gerekmektedir. Bu olgu sunumunda, tekrarlayan anormal found to have GPS. kanama atakları olan ve GPS bulgusu bulunan bir vaka sunulmaktadır. Key words: Bleeding disorder, gray platelet syndrome, Anahtar
    [Show full text]
  • Supplemental Figure Legends
    Supplemental Figure Legends: Supplemental Figure 1. Disruption of DIAPH1 gene expression and example of ingressions found in DIAPH1-deficient cultures. A) Western blot analysis of HaCaT cells transduced with non-targeting (NT) and DIAPH1-directed (Dia1) shRNA via lentivirus, cultured in low or high calcium media for 20hrs. Relative abundance indicated with respect to control samples. B) Western blot analysis of control cells (CTL) and those carrying a disrupted DIAPH1 locus (CRISPR) at two different passages. Relative abundance to controls is indicated. C) NGS analysis of genomic DNA flanking CRISPR-editing site and variant frequency. D) Example of DIAPH1-deficient tissue growth into the underlying collagen substrate. Hematoxylin and eosin stain of cross- sectioned, paraffin-embedded tissue fixed 10 days after raising to an air-liquid interface. Scale bar= 20 microns. Yellow arrow indicates basal keratinocyte layer. Red arrows indicate distinct ingressions. Supplemental Figure 2. Organotypic cultures treated with shRNA, ectopic mDia1 constructs and ancillary RNA-seq data. A) Hematoxylin and eosin (H&E) staining and keratin-10 (KRT10) staining of organotypic cultures transduced with control or Dia1- targeted shRNA. Counterstained with Hoechst for DNA. Dotted line indicates keratinocyte/collagen boundary. Scale bars = 20μm. B) Map of mDia1 construct introduced to CRISPR-edited Dia1 knockdown (Dia1KD) cells via lentivirus. Numerals are referenced in subsequent panels. FL= full length. C and D) Western blot analysis of ectopic constructs blotted with anti-DIAPH1 (C) or anti-Cherry (D). Residual Scarlet signal indicated by arrowhead. Irrelevant lanes of western blot lanes were dimmed for clarity. E) RNA-seq analysis of DIAPH1 transcripts in CRISPR-edited Dia1KD cells.
    [Show full text]
  • Wessex Regional Genetics Laboratory Publications for 2017
    Wessex Regional Genetics Laboratory Publications for 2017 Alikian M, Whale AS, Akiki S, Piechocki K, Torrado C, Myint T, Cowen S, Griffiths M, Reid AG, Apperley J, White H , Huggett JF, Foroni L. RT-qPCR and RT-Digital PCR: A comparison of different platforms for the evaluation of residual disease in chronic myeloid leukemia. Clin Chemistry 2017 63.2 :525-531. Butt NM, Lambert J, Ali S, Beer PA, Cross NCP , Duncombe A, Ewing J, Harrison CN, Knapper S, McLornan D, Mead AJ, R D, Bain BJ, on behalf of the British Committee for Standards in Haematology. Guideline for the investigation and management of eosinophilia. Br J Haemat 2017 176 : 553-572. Cooper R, Markham H, Theaker J, Bateman A, Bunyan D , Sommerlad M, Crawford G, Eccles D. Case Report: Primary clear cell microcystic adenoma of the sinonasal cavity: pathological or fortuitous association? Hindawi 2017 doi.org/10.1155/2017/9236780. Defour J-P, Hoade Y, Reuther A-M, Callaway A , Ward D , Chen F, Constantinescu SN, Cross ~NCP . An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis. Leukemia 2017 Letters to the Editor 31 : 1838-1839. Ghazzawi M, Mehra V, Knut M, Brown L, Tapper W, Chase A , de Lavallade H, Cross NCP . A novel PCM1-PDGFRB fusion in a patient with a chronic myeloproliferative neoplasm and an ins(8;5). Acta Haematol 2017 138 :198-200. Giles FJ, Rea D, Rosti G, Cross NCP , Steegmann JL, Griskevicius L, le Coutre P, Coriu D, Petrov L, Ossenkoppele GJ, Mahon F-X, Saussele S, Hellmann A, Koskenvesa P, Brümmendorf TH, Gastl G, Castagnetti F, Vincenzi B, Haenig J, Hochhaus A.
    [Show full text]
  • DIAPH1 Mutation As a Novel Cause of Autosomal Dominant Macro Thrombocytopenia and Hearing Loss
    Open Access Annals of Hematology & Oncology Case Report DIAPH1 Mutation as a Novel Cause of Autosomal Dominant Macro Thrombocytopenia and Hearing Loss Karki R1*, Heilegiorgis Ajebo G2, Savage N3 and Kutlar A4 Abstract 1Division of Hematology and Oncology, Medstar Harbor Macrothrombocytopenia (MTP) is a group of rare disorders characterized by Hospital, USA giant platelets, thrombocytopenia and variably associated with abnormal bleeding. 2Division of Hematology and Oncology, Augusta Inherited MTP are frequently misdiagnosed as immune thrombocytopenia. University, USA Associated second organ manifestation can help narrow down syndromic MTPs. 3Department of Pathology, Augusta University, USA We describe a case of autosomal dominant sensorineural hearing loss and MTP 4Division of Hematology, Augusta University, USA caused by a gain of function mutation in DIAPH1. This mutation causes altered *Corresponding author: Nabin Raj Karki, Division megarkaryopoiesis and platelet cytoskeletal deregulation. Although hearing loss of Hematology and Oncology, Medstar Harbor Hospital, and MTP is likely progressive, clinically significant bleeding was not observed. 3001 S Hanover St, Baltimore, 20160, USA DIAPH1 related MTP can be distinguished clinically from MYH9 mutation by the absence of cataracts and glomerular disease. Received: December 18, 2019; Accepted: February 13, 2020; Published: February 20, 2020 Introduction Macrothrombocytopenia (MTP) is a heterogeneous group of rare disorders characterized by enlarged circulating platelets that are reduced in number and variably associated with abnormal bleeding. A vast majority of MTPs are acquired. Not uncommonly, inherited thrombocytopenia’s are wrongly diagnosed as immune thrombocytopenia’s and patient’s receive futile treatments. A careful search for associated secondary feature may help guide a workup to identify specific genetic aberration.
    [Show full text]
  • Anti-DIAPH1 Antibody (ARG55315)
    Product datasheet [email protected] ARG55315 Package: 100 μl anti-DIAPH1 antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes DIAPH1 Tested Reactivity Hu, Ms, Rat Tested Application IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name DIAPH1 Antigen Species Human Immunogen Recombinant protein of Human DIAPH1 Conjugation Un-conjugated Alternate Names DRF1; Diaphanous-related formin-1; LFHL1; DFNA1; Protein diaphanous homolog 1; hDIA1; DIA1 Application Instructions Application table Application Dilution IHC-P 1:50 - 1:200 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control Mouse lung and HepG2 Calculated Mw 141 kDa Properties Form Liquid Purification Affinity purification with immunogen. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. www.arigobio.com 1/2 Bioinformation Database links GeneID: 1729 Human Swiss-port # O60610 Human Gene Symbol DIAPH1 Gene Full Name diaphanous-related formin 1 Background This gene is a homolog of the Drosophila diaphanous gene, and has been linked to autosomal dominant, fully penetrant, nonsyndromic sensorineural progressive low-frequency hearing loss.
    [Show full text]
  • Platelet Function Disorders
    TREATMENT OF HEMOPHILIA APRIL 2008 • NO 19 PLATELET FUNCTION DISORDERS Second Edition Anjali A. Sharathkumar Amy Shapiro Indiana Hemophilia and Thrombosis Center Indianapolis, U.S.A. Published by the World Federation of Hemophilia (WFH), 1999; revised 2008. © World Federation of Hemophilia, 2008 The WFH encourages redistribution of its publications for educational purposes by not-for-profit hemophilia organizations. In order to obtain permission to reprint, redistribute, or translate this publication, please contact the Communications Department at the address below. This publication is accessible from the World Federation of Hemophilia’s website at www.wfh.org. Additional copies are also available from the WFH at: World Federation of Hemophilia 1425 René Lévesque Boulevard West, Suite 1010 Montréal, Québec H3G 1T7 CANADA Tel. : (514) 875-7944 Fax : (514) 875-8916 E-mail: [email protected] Internet: www.wfh.org The Treatment of Hemophilia series is intended to provide general information on the treatment and management of hemophilia. The World Federation of Hemophilia does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. Dose schedules and other treatment regimes are continually revised and new side effects recognized. WFH makes no representation, express or implied, that drug doses or other treatment recommendations in this publication are correct. For these reasons it is strongly recommended that individuals seek the advice of a medical adviser and/or consult printed instructions provided by the pharmaceutical company before administering any of the drugs referred to in this monograph. Statements and opinions expressed here do not necessarily represent the opinions, policies, or recommendations of the World Federation of Hemophilia, its Executive Committee, or its staff.
    [Show full text]
  • Stritt, S., Nurden, P., Turro, E., Greene, D., Jansen, SB, Westbury
    Stritt, S., Nurden, P., Turro, E., Greene, D., Jansen, S. B., Westbury, S. K., Petersen, R., Astle, W. J., Marlin, S., Bariana, T. K., Kostadima, M., Lentaigne, C., Maiwald, S., Papadia, S., Kelly, A. M., Stephens, J. C., Penkett, C. J., Ashford, S., Tuna, S., ... Mumford, A. D. (2016). A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss. Blood, 127(23), 2903-2914. https://doi.org/10.1182/blood-2015-10-675629 Peer reviewed version Link to published version (if available): 10.1182/blood-2015-10-675629 Link to publication record in Explore Bristol Research PDF-document This is the author accepted manuscript (AAM). The final published version (version of record) is available online via the American Society of Hematology at http://www.bloodjournal.org/content/127/23/2903. Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ A gain-of-function DIAPH1 variant causes dominant macrothrombocytopenia and hearing loss Running title: DIAPH1 and macrothrombocytopenia Authors: Simon Stritt1*, Paquita Nurden2,3*, Ernest Turro4-7,*, Daniel Greene4,6,7, Sjoert B Jansen4,5, Sarah K Westbury8, Romina Petersen4,5, William J Astle4-6, Sandrine Marlin9, Tadbir K Bariana10,11, Myrto Kostadima4,5, Claire Lentaigne12,13,
    [Show full text]
  • The Integrity of Cochlear Hair Cells Is Established and Maintained
    Ninoyu et al. Cell Death and Disease (2020) 11:536 https://doi.org/10.1038/s41419-020-02743-z Cell Death & Disease ARTICLE Open Access The integrity of cochlear hair cells is established and maintained through the localization of Dia1 at apical junctional complexes and stereocilia Yuzuru Ninoyu1,2, Hirofumi Sakaguchi2, Chen Lin1, Toshiaki Suzuki 1, Shigeru Hirano2,YasuoHisa2, Naoaki Saito1 and Takehiko Ueyama 1 Abstract Dia1, which belongs to the diaphanous-related formin family, influences a variety of cellular processes through straight actin elongation activity. Recently, novel DIA1 mutants such as p.R1213X (p.R1204X) and p.A265S, have been reported to cause an autosomal dominant sensorineural hearing loss (DFNA1). Additionally, active DIA1 mutants induce progressive hearing loss in a gain-of-function manner. However, the subcellular localization and pathological function of DIA1(R1213X/R1204X) remains unknown. In the present study, we demonstrated the localization of endogenous Dia1 and the constitutively active DIA1 mutant in the cochlea, using transgenic mice expressing FLAG-tagged DIA1 (R1204X) (DIA1-TG). Endogenous Dia1 and the DIA1 mutant were regionally expressed at the organ of Corti and the spiral ganglion from early life; alongside cochlear maturation, they became localized at the apical junctional complexes (AJCs) between hair cells (HCs) and supporting cells (SCs). To investigate HC vulnerability in the DIA1-TG mice, we exposed 4-week-old mice to moderate noise, which induced temporary threshold shifts with cochlear synaptopathy and ultrastructural changes in stereocilia 4 weeks post noise exposure. Furthermore, we established a knock-in (KI) fi 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; mouse line expressing AcGFP-tagged DIA1(R1213X) (DIA1-KI) and con rmed mutant localization at AJCs and the tips of stereocilia in HCs.
    [Show full text]
  • A Comprehensive Review on Inherited Sensorineural Hearing Loss and Their Syndromes
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 14 August 2020 doi:10.20944/preprints202008.0308.v1 Manuscript (Review Article) A comprehensive review on inherited Sensorineural Hearing Loss and their syndromes Authors Muhammad Noman 1, Shazia Anwer Bukhari 1, Muhammad Tahir 2, & Shehbaz Ali 3* Author’s information 1 Department of Biochemistry, Molecular Biology laboratory, Government College, University, Faisalabad, 38000, Pakistan. 2 Department of Oncology, Allied Teaching Hospital Faisalabad, Faisalabad Medical University, Faisalabad, 38000, Pakistan. 3 Department of Biosciences and Technology, Khwaja Fareed University of Engineering and information technology, Rahim Yar Khan, Punjab, Pakistan. *Correspondence: Shehbaz Ali: [email protected] Tel: +92-333-7477407 Abstract Hearing impairment is an immensely diagnosed genetic cause, 5% of the total world population effects with different kind of congenital hearing loss (HL). In third-world countries or countries where consanguineous marriages are more common the frequency rate of genetic disorders are at its zenith. Approximately, the incidence of hearing afflictions is ostensibly 7-8:1000 individuals whereas it is estimated that about 466 million peoples suffer with significant HL, and of theses deaf cases 34 million are children’s up to March, 2020. Several genes and colossal numbers of pathogenic variants cause hearing impairment, which aided in next-generation with recessive, dominant or X-linked inheritance traits. This review highlights on syndromic and non-syndromic HL (SHL and NSHL), and categorized as conductive, sensorineural and mixed HL, which having autosomal dominant and recessive, and X-linked or mitochondrial mode of inheritance. Many hundred genes involved in HL are reported, and their mutation spectrum becomes very wide.
    [Show full text]